ページの先頭です
HOME > Past Issue List > Issue List > Abstract
言語を選択(Language)
日本語(Japanese)English

Abstract

Vol.67 No.6 November 2019

Diagnosis and management of drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DiHS/DRESS)

Yoshiko Mizukawa and Tetsuo Shiohara

Department of Dermatology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, Japan

Abstract

Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DiHS/DRESS) is a life-threatening multiorgan system reaction caused by a limited number of drugs, including carbamazepine, phenytoin, phenobarbital, zonisamide, allopurinol, lamotrigine, salazosulfapyridine, and mexiletine. However, this syndrome has several unique clinical features that cannot be solely explained by drug allergy. DiHS/DRESS is characterized by a paradoxical deterioration of clinical symptoms, frequent flare-ups and a stepwise development of several organs system failures multiorgan failure after withdrawal of the causative drug. We demonstrated that several herpes viruses, especially human herpesvirus 6 (HHV-6), could be reactivated during this syndrome in a sequential order, as demonstrated in other settings of the immune reconstitution inflammatory syndrome (IRIS). Given the observation that paradoxical worsening of the clinical symptoms is typically observed after withdrawal of the causative drugs with immunosuppressive properties at the onset of DiHS/DRESS, it is attractive to suppose that DiHS/DRESS is a manifestation of non-HIV IRIS. Various infections have been noted in corticosteroid-treated patients with DiHS/DRESS, including herpes simplex, herpes zoster, Pneumocystis jirovecii pneumonia, and cytomegalovirus diseases. Of note, most infectious diseases appeared within 1 month, and coincided with a tapering of the corticosteroid dose. This paper presents clinical features of DiHS/DRESS, and a management-based approach to the diagnosis and treatment.

Key word

drug-induced hypersensitivity syndrome, drug reaction with eosinophilia and systemic symptoms, immune reconstitution inflammatory syndrome

Received

October 29, 2018

Accepted

June 25, 2019

Jpn. J. Chemother. 67 (6): 620-627, 2019